Navigation Links
Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast'
Date:8/10/2011

MUMBAI, August 10, 2011 /PRNewswire/ --


  • Revamilast is a PDE4 inhibitor, under development for Asthma, Rheumatoid Arthritis and other inflammatory disorders
  • The molecule successfully completed pre-clinical trials and Phase I studies
    • Phase I studies on healthy volunteers were carried out mainly in the UK
  • Glenmark has initiated global  Phase IIb studies for both indications in Europe and Asia
  • Huge unmet medical need as globally they are over 300 million Asthma patients and over 20 million Rheumatoid Arthritis patients

Glenmark Pharmaceuticals today announced that its Novel Chemical Entity "Revamilast" (GRC 4039) has initiated Phase IIb human dose range finding trials globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as  Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases. The Phase IIb studies that will be carried out will help establish the efficacy and safety of the molecule and will also provide dose range finding data for Revamilast.

Dr. Steffen Stuerzebecher, President & Chief Medical Officer, Glenmark Pharmaceuticals Ltd said "The clinical trials and the animal studies data for Revamilast are promising for both indications i.e. Asthma and Rheumatoid Arthritis. There is a huge unmet need for both these chronic medical conditions globally. For Glenmark, this is a significant development as we have built on more than a decade of experience in the PDE 4 space to progress an exciting molecule to Phase II human trials."

In Phase I studies carried out mainly in the United Kingdom, nearly 150 healthy volunteers have been dosed and no Serious Adverse Events have been noted. The pharmacodynamic evaluation in healthy hum
'/>"/>

SOURCE Glenmark Pharmaceuticals Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Glenmark Announces the Discovery of a Novel Chemical Entity GRC 17536, a TRPA1 Receptor Antagonist, a Potential First-in-Class Molecule Globally
2. Glenmarks Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials
3. SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London
4. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
5. BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
6. InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF
7. GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine
8. CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis
9. Metabolex Initiates Phase 2 Trial of Arhalofenate
10. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
11. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... to $5.8 million and provides a good start to Q4.  The ... America and one in the Middle East ... record levels," said Peter Bruijns , President & CEO. "Total ... Q3 than they have been for any complete year since the ...
(Date:10/20/2014)... Earle Martin , Chief ... that Ellen Teplitzky, an experienced attorney specializing in ... industry, has joined the firm as Director of ... practice. NDA Partners provides legal services, including ... to top law firms and their clients in ...
(Date:10/19/2014)... The Asia-Pacific Bromine Market report defines and ... and forecast of revenue. , Browse through the ... to get an idea of the in-depth analysis ... segmentation in the Asia-Pacific bromine market, and is ... http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine is a volatile ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... (Amex: IMA ) today announced that it has ... Australian company traded on,the Australian Securities Exchange, under which ... issued shares in Panbio for AUD 0.65 cash,per share. ... of,Panbio at approximately AUD 41 million, or approximately USD ...
... ExL Pharma, Cision and the PRSA have,joined ... biotech,public relations executives the first Pharmaceutical Public Relations,Symposium ... This,one-day event will cover the key issues and ... is under ongoing political and media scrutiny,most notably ...
... USC,s Increased Commitment to Research Advancements in Health ... Robust Life Science Industry in Los Angeles, LOS ... University of Southern California,s strengthened,commitment to advancing breakthrough research ... today the opening of an office,in the new Harlyne ...
Cached Biology Technology:Inverness Medical Innovations Agrees to Acquire Panbio Ltd. 2Leading Pharmaceutical Communication Executives Gather for the 1st Annual Pharmaceutical Public Relations Symposium 2The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus 2The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus 3The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus 4
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
(Date:10/17/2014)... the University of Copenhagen have shown for the first ... of Cystic fibrosis patients, giving them the opportunity to ... chronic infections. , The study also discovered the bacterial ... patients was halted or slowed down by the immune ... the oxygen and helped "suffocate" the bacteria, forcing the ...
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2
... using highly sophisticated equipment. Yet the Florida State University geochemist ... Tibet and camping in the foothills of the Himalayas ... that unique mix of skills, Wang was chosen to take ... prehistoric woolly rhino ever found. A paper describing the team,s ...
... WASHINGTON, D.C. The American Association for Cancer ... Science of Cancer Health Disparities from Sept. 18-21, 2011, ... This conference will bring together scientists, survivors, ... cancer genetics, epidemiology and treatment methods to better meet ...
... pheromone-baited bucket traps, canines to sniff out breeding sites, ... the coconut rhinoceros beetle (CRB) on Guam with the ... tactics. USDA has given Guam an infusion of cash ... population on island. Aubrey Moore, entomologist and researcher with ...
Cached Biology News:A wild and woolly discovery: FSU scientist's Tibetan expedition ends with prehistoric find 2A wild and woolly discovery: FSU scientist's Tibetan expedition ends with prehistoric find 3AACR to host conference on the science of cancer health disparities 2
... Transformation Kit is designed for rapid ... Advantages over commonly used transformation procedures ... methods include:- Cells can be made competent ... cell preparation and transformation solutions are ...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
...
... Error-free cloning of BAC (100+kb), fosmid (40kb), ... insert stability than any othe BAC vector. ... high yields and easy recombinant DNA purification. ... transcription-free (pSMART VC) vectors for the highest ...
Biology Products: